Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...
Shares of Catalyst Pharmaceuticals ( CPRX ) have risen by 30% since my May article noted that the panic selling on FDA approval of Jacobus Pharma's Ruzurgi appeared overdone. I certainly failed to nail the bottom, but despite this surprising move by the regulatory agency, much of the long th...
Editor's note: Seeking Alpha is proud to welcome Illuminate Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's not...
Key investment thesis: Catalyst Pharmaceuticals ( CPRX ) stock is cut in more than half after FDA approved rival Jacobus’s therapy Ruzurgi (3,4-DAP) in treating pediatric Lambert-Eaton myasthenic syndrome, LEMS. Investors feared two things: (1) Prescribing clinicians may prefer to p...
Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM...
CORAL GABLES, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and re...
CORAL GABLES, Fla., June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) has amended its license agreement for Firdapse to expand its commercial territory. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CORAL GABLES, Fla., May 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) discloses that it has settled a patent dispute with Northwestern University related to pipeline candidate CPP-115. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...